Unitaid transparency policy
Policy on ethics and conflict of interest for Unitaid
Unitaid’s climate and health strategy 2023-2027
Unitaid’s investment case 2023-2027, executive summary
Unitaid’s investment case 2023-2027
Unitaid Strategy 2023-2027
Maternal and newborn health
Women’s and children’s health
Building climate-resilient, sustainable, and low-carbon health supply chains: key priorities for collective action
Gonorrhea point-of-care diagnostics technology and market landscape
Screening and treatment of precancerous lesions for secondary prevention of cervical cancer
Landscape report on commodity and service delivery innovations for detection and management of pre-eclampsia
Medical oxygen innovation landscape
The untold story of dolutegravir: When climate impact goes hand-in-hand with access to better treatments
Antimalarial manufacturing in Africa: A call for regional action
Enabling a market-based approach to manufacturing quality-assured health products in Africa: A differentiated coordination approach
Unitaid audited financial report for the year ended 31 December 2021
Unitaid audited financial report for the year ended 31 December 2020
Unitaid audited financial report for the year ended 31 December 2019
Unitaid audited financial report for the year ended 31 December 2018
Safeguarding – supplemental annex to Unitaid wrongdoing guidelines
FAQ – Financial Guidelines
Guidelines prevention, reporting and management of wrongdoing
Impact story: Expanding access to next generation drug-resistant tuberculosis treatment
Unitaid’s Impact 2017 Results and Key Performance Indictors
